Holen Sie sich die Stockscreener-App
104.85
2.03%
2.09
Schlusskurs vom Vortag:
$102.76
Offen:
$102.9
24-Stunden-Volumen:
892.23K
Relative Volume:
0.43
Marktkapitalisierung:
$13.62B
Einnahmen:
$902.57M
Nettoeinkommen (Verlust:
$-398.79M
KGV:
-32.63
EPS:
-3.2131
Netto-Cashflow:
$-274.52M
1W Leistung:
+2.95%
1M Leistung:
-1.91%
6M Leistung:
+79.02%
1J Leistung:
+123.18%
1-Tages-Spanne:
$102.75
$106.42
1-Wochen-Bereich:
$99.50
$108.51
52-Wochen-Spanne:
$34.88
$120.74
Guardant Health Inc Stock (GH) Company Profile
Firmenname
Guardant Health Inc
Sektor
Branche
Telefon
855-698-8887
Adresse
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
104.85 | 13.35B | 902.57M | -398.79M | -274.52M | -3.2131 |
|
TMO
Thermo Fisher Scientific Inc
|
504.82 | 191.54B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
212.58 | 151.94B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
629.35 | 49.28B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
125.81 | 35.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
323.37 | 31.37B | 3.17B | 642.63M | 539.81M | 10.77 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-09-25 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-28 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-11-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-04-28 | Fortgesetzt | BTIG Research | Buy |
| 2022-02-24 | Bestätigt | Canaccord Genuity | Buy |
| 2022-02-24 | Bestätigt | Citigroup | Buy |
| 2022-02-24 | Bestätigt | Cowen | Outperform |
| 2022-02-24 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-24 | Bestätigt | SVB Leerink | Outperform |
| 2022-02-24 | Bestätigt | Stifel | Buy |
| 2022-02-24 | Bestätigt | Wells Fargo | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-11 | Eingeleitet | Stifel | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-06-12 | Eingeleitet | BTIG Research | Buy |
| 2020-02-21 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-08-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-04-16 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-04-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Bestätigt | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-29 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Guardant Health Inc Aktie (GH) Neueste Nachrichten
Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why (GH) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Cancer Profiling Market Size, Share | Growth Report [2034] - Fortune Business Insights
Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open - Yahoo Finance
GoFundMe for James Van Der Beek’s family surpasses $1.5M in less than 24 hours - Austin American-Statesman
Guardant Health Shares Slide as Principal Cuts Stake and Insiders Sell - CryptoRank
Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Guardant Health, Inc. $GH Shares Sold by Principal Financial Group Inc. - MarketBeat
Travel Stocks: How does Guardant Health Inc compare to its peersJuly 2025 Levels & Fast Gain Swing Alerts - baoquankhu1.vn
Guardant Health (GH) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Guardant Health Inc (GH) Trading Down 4.5% on Feb 11 - GuruFocus
Minimal Residual Disease Testing Market Poised for Rapid Growth - openPR.com
Aug Momentum: Is now the right time to enter Guardant Health IncJuly 2025 Fed Impact & Verified Stock Trade Ideas - baoquankhu1.vn
New York State Common Retirement Fund Has $4.77 Million Stake in Guardant Health, Inc. $GH - MarketBeat
IQ EQ FUND MANAGEMENT IRELAND Ltd Lowers Position in Guardant Health, Inc. $GH - MarketBeat
Top Cancer Stocks for 2026 and How to Invest - The Motley Fool
A Congress Member Sold Up To $125K In McDonald's Stock: Here's What You Need To Know - Benzinga
ETF Watch: Is now the right time to enter Guardant Health Inc2025 Volume Leaders & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Guardant Health to Participate in Upcoming Investor ConferencesFebruary 3, 2026 - BioSpace
Precision oncology firm Guardant lines up four investor talks - stocktitan.net
Guardant Health ctDNA test sets new standard in cancer detection - Traders Union
Guardant Health guides Q4 and FY25 revenue above consensus - MSN
Understanding Momentum Shifts in (GH) - Stock Traders Daily
Merck Eyes Post Keytruda Growth With Eikon Stake And Guardant Pact - Yahoo Finance
Guardant Health (GH) Study Highlights Advancements in Colon Canc - GuruFocus
Guardant Health, Inc. (GH) Stock Analysis: A Precision Oncology Pioneer with 9.82% Upside Potential - DirectorsTalk Interviews
ctDNA blood test better predicts colon cancer recurrence than standard staging - Investing.com
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions - Business Wire
Blood test flags colon cancer patients most likely to see disease return - Stock Titan
Aug Intraday: Can Guardant Health Inc benefit from deglobalizationWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
Knights of Columbus Asset Advisors LLC Takes Position in Guardant Health, Inc. $GH - MarketBeat
Assessing Guardant Health (GH) Valuation After FDA Guardant360 CDx Approval And New Merck Collaboration - Yahoo Finance
UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating - marketscreener.com
Should You Buy Guardant Health Before Feb. 19? - The Globe and Mail
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Business Wire
Guardant Health, Inc. $GH Shares Bought by Federated Hermes Inc. - MarketBeat
Merger Talk: What are the future prospects of Guardant Health IncWeekly Loss Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Risk Analysis: Does Tripadvisor Inc have declining or rising EPSJuly 2025 Reactions & Precise Buy Zone Tips - baoquankhu1.vn
Guardant Health Inc (GH) Shares Down 3.74% on Jan 28 - GuruFocus
Strs Ohio Boosts Holdings in Guardant Health, Inc. $GH - MarketBeat
Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 23% Undervaluation? - 富途牛牛
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Regeneron (REGN) - The Globe and Mail
Guggenheim Raises Price Target on Guardant Health (GH) to $135 | GH Stock News - GuruFocus
Guardant Health: Look For Explosive Revenue Growth Ahead (NASDAQ:GH) - Seeking Alpha
Y Intercept Hong Kong Ltd Has $4.77 Million Holdings in Guardant Health, Inc. $GH - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Guardant Health (GH) - The Globe and Mail
Universal Beteiligungs und Servicegesellschaft mbH Acquires 106,263 Shares of Guardant Health, Inc. $GH - MarketBeat
Baillie Gifford & Co. Increases Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health (GH): Court Decision Offers Incremental Positive in Litigation - GuruFocus
Leerink Partners Maintains Guardant Health(GH.US) With Buy Rating - 富途资讯
Guardant Can Try Again To Nix Patent Tied To $83M Verdict - Law360
Finanzdaten der Guardant Health Inc-Aktie (GH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):